Applications for this meeting must be submitted by May 27, 2017. Please apply early, as some meetings become oversubscribed (full) before this deadline. If the meeting is oversubscribed, it will be stated here. Note: Applications for oversubscribed meetings will only be considered by the Conference Chair if more seats become available due to cancellations.
GRS Speaker Abstract Deadline: Although applications will be accepted until the date noted above, any applicants who wish to be considered for an oral presentation should submit their application by March 24, 2017. Please refer to the application instructions in the Meeting Description section below for more details (if available).
The Gordon Research Seminar on Parkinson's Disease is a unique forum for graduate students, post-docs, and other scientists with comparable levels of experience and education to present and exchange new data and cutting edge ideas.
Parkinson's Disease Gordon Research Seminar (GRS) will be the first Gordon meeting
designed specifically for trainees studying Parkinson's disease, composed of a
two-day meeting incorporating Graduate Student and Postdoc presentations with experts
in the field. In addition to trainee platform and poster presentations, the
2017 GRS will include a special presentation from an individual living with
Parkinson's disease, and a career panel encompassing multiple sectors of the PD
field (academia, industry, granting agencies, scientific journals, foundations).
The scientific focus of this meeting will encompass pathological mechanisms of
PD, therapeutic interventions, and novel methods in disease detection and
The meeting will feature approximately 10 talks and 2 poster sessions. All attendees are expected to actively participate in the GRS either by giving an oral presentation or presenting a poster. Therefore, all applications must include an abstract.
The Chairs will select speakers from abstracts submitted by March 24, 2017. Those applicants who are not chosen for talks and those who apply after the deadline to be considered for an oral presentation will be expected to present a poster. In order to participate, you must submit an application by the date indicated in the Application Deadline section above.
This GRS will be held in conjunction with the "Parkinson's Disease" Gordon Research Conference (GRC)
. Those interested in attending both meetings must submit an application for the GRC in addition to an application for the GRS. Refer to the associated GRC program page
for more information.
|2:00 pm - 5:00 pm||Arrival and Check-in|
|3:30 pm - 3:45 pm||Introductory Comments by GRC Site Staff / Welcome by the GRS Conference Chair|
|3:45 pm - 4:30 pm||Keynote Session: Modeling and Treating Parkinson's Disease Using Human Pluripotent Stem Cells|
|Discussion Leader: Andrew Singleton (National Institutes of Health, USA)|
|3:45 pm - 4:20 pm||Lorenz Studer (Memorial Sloan Kettering Cancer Center, USA)|
"Modeling and Treating Parkinson's Disease Using Human Pluripotent Stem Cells"
|4:20 pm - 4:30 pm||Discussion|
|4:30 pm - 6:00 pm||Poster Session|
|7:30 pm - 9:30 pm||Molecular Mechanisms in Parkinson's Disease|
|Discussion Leader: Briana De Miranda (University of Pittsburgh, USA)|
|7:30 pm - 7:55 pm||Valerie Joers (Emory University, USA)|
"Modulation of Inflammation via Cannabinoid Type 2 Receptors to Protect Against Asyn-Induced Degeneration"
|7:55 pm - 8:00 pm||Discussion|
|8:00 pm - 8:25 pm||Stefano Cataldi (Centre for Applied Neurogenetics, Canada)|
"Characterization of the VPS35 p.D620N Knock-In Mouse Model of Parkinson's Disease"
|8:25 pm - 8:30 pm||Discussion|
|8:30 pm - 8:55 pm||Nora Bengoa-Vergniory (Oxford Parkinson's Disease Center, United Kingdom)|
"Mass-Spectrometry Approach Highlights REST as a Potential Neuroprotective Target for Parkinson's disease in an Alpha Synuclein Overexpressing BAC-Transgenic Mouse Model"
|8:55 pm - 9:00 pm||Discussion|
|9:00 pm - 9:25 pm||Gelareh Alam (Northeast Ohio Medical University, USA)|
"Tyrosine Hydroxylase Decrease Independent of Neuronal Loss Following Toxin-Induced Animal Models of Parkinson's Disease"
|9:25 pm - 9:30 pm||Discussion|
|7:30 am - 8:30 am||Breakfast|
|9:00 am - 11:00 am||Parkinson's Disease in the Clinic|
|Discussion Leader: J. Timothy Greenamyre (University of Pittsburgh, USA)|
|9:00 am - 9:20 am||Introduction by Discussion Leader: Clinical Diagnosis and Presentation of Parkinson's Disease|
|9:20 am - 9:45 am||Nicole LaBolle (University of Pittsburgh, USA)|
"Living with Parkinson's Disease"
|9:45 am - 10:00 am||Discussion|
|10:00 am - 10:25 am||Karl Heilbron (23andMe, USA)|
"Traits Associated with Parkinson's Disease in a Large and Deeply Phenotyped Cohort"
|10:25 am - 10:30 am||Discussion|
|10:30 am - 10:55 am||Katherine Strynatka (Dalhousie University, Canada)|
"Identifying Small Molecule Inhibitors of ArfGAP1 Toward a Potential Treatment for LRRK2 Mediated Parkinson's Disease"
|10:55 am - 11:00 am||Discussion|
|11:00 am - 12:30 pm||Poster Session|
|Coffee will be served in the poster area from 11:00 am - 11:30 am|
|1:30 pm - 2:30 pm||Mentorship Component: Catalyzing a New Career|
|Crafting high impact manuscripts to propel your career trajectory; inside and outside of academia.|
|Discussion Leader: Meghan Bucher (University of Pittsburgh, USA)|
|1:30 pm - 1:50 pm||Orla Smith (Science Translational Medicine, AAAS, USA)|
"Breaching Barriers in Scientific Publishing"
|1:50 pm - 2:00 pm||Discussion|
|2:00 pm - 2:30 pm||Panel Discussion|
|"Expanding the Approach of Career Development"|
- Brian Fiske (The Michael J. Fox Foundation for Parkinson's Research, USA)
- Ian Reynolds (Teva Pharmaceutical Industries, USA)
- Margaret Sutherland (National Institute of Neurological Disorders and Stroke, NIH, USA)
- Malu Tansey (Emory University, USA)
|2:30 pm - 3:00 pm||Evaluation Period|
|Fill in GRS Evaluation Forms|
|3:00 pm||Seminar Concludes|
Research reported in this publication was supported by the National Institute of Neurological Disorders And Stroke of National Institutes of Health under Award Number R13NS100272. The content is solely the responsibility of the authors and does not necessarily represent official views of the National Institutes of Health.